Posts Archive

NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma

NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma

NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)

The PCROWD Study invites people with precursor conditions to Share samples a few times each year

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL

NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5

NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM

NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM

NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma

NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM

NCT04634435: Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in NDMM

IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test

NCT04484623: Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)